Healthcare giant Johnson & Johnson’s (JNJ) third-quarter earnings results are due on Tuesday before the bell. While the constant threat from biosimilars looms over the company, Johnson and Johnson will be looking at growth in Pharmaceutical and Medical Devices businesses to drive the stock rally. Analysts, on an average, expect the company to report earnings … Continue reading Biosimilars might haunt Johnson & Johnson in Q3 as well